This article is- freely available
- re-usable
Review
Efficacy of CMX001 as a Post Exposure Antiviral in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans
Amanda D. Rice 1 
,
Mathew M. Adams 1 
,
Greg Wallace 1 
,
Andrew M. Burrage 1 
,
Scott F. Lindsey 1 
,
Andrew J. Smith 1 
,
Daniele Swetnam 1 
,
Brandi R. Manning 1 
,
Stacey A. Gray 1 
,
Bernhard Lampert 2 
,
Scott Foster 2 
,
Randall Lanier 2 
,
Alice Robertson 2 
,
George Painter 2 
and
Richard W. Moyer 1,*

1
Department of Molecular Genetics and Microbiology, University of Florida, 1600 SW Archer Rd, Gainesville, FL 32610, USA
2
Chimerix, Inc., 2505 Meridian Parkway Suite, 340 Durham, NC 27713, USA
* Author to whom correspondence should be addressed.
Received: 1 December 2010; in revised form: 4 January 2011 / Accepted: 5 January 2011 / Published: 24 January 2011
Abstract: CMX001, a lipophilic nucleotide analog formed by covalently linking 3-(hexdecyloxy)propan-1-ol to cidofovir (CDV), is being developed as a treatment for smallpox. In the absence of human cases of smallpox, new treatments must be tested for efficacy in animal models. Previously, we demonstrated the efficacy of CMX001 in protecting New Zealand White rabbits from mortality following intradermal infection with rabbitpox virus as a model for smallpox, monkeypox and for treatment of adverse reactions to smallpox vaccination. Here we extend these studies by exploring different dosing regimens and performing randomized, blinded, placebo-controlled studies. In addition, because rabbitpox virus can be transmitted via naturally generated aerosols (animal to animal transmission), we report on studies to test the efficacy of CMX001 in protecting rabbits from lethal rabbitpox virus disease when infection occurs by animal to animal transmission. In all cases, CMX001 treatment was initiated at the onset of observable lesions in the ears to model the use of CMX001 as a treatment for symptomatic smallpox. The results demonstrate that CMX001 is an effective treatment for symptomatic rabbitpox virus infection. The rabbitpox model has key similarities to human smallpox including an incubation period, generalized systemic disease, the occurrence of lesions which may be used as a trigger for initiating therapy, and natural animal to animal spread, making it an appropriate model.
Keywords: poxvirus; antiviral; CMX001; rabbitpox; smallpox treatment
Article Statistics
Click here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Rice, A.D.; Adams, M.M.; Wallace, G.; Burrage, A.M.; Lindsey, S.F.; Smith, A.J.; Swetnam, D.; Manning, B.R.; Gray, S.A.; Lampert, B.; Foster, S.; Lanier, R.; Robertson, A.; Painter, G.; Moyer, R.W. Efficacy of CMX001 as a Post Exposure Antiviral in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans. Viruses 2011, 3, 47-62.
AMA Style
Rice AD, Adams MM, Wallace G, Burrage AM, Lindsey SF, Smith AJ, Swetnam D, Manning BR, Gray SA, Lampert B, Foster S, Lanier R, Robertson A, Painter G, Moyer RW. Efficacy of CMX001 as a Post Exposure Antiviral in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans. Viruses. 2011; 3(1):47-62.
Chicago/Turabian Style
Rice, Amanda D.; Adams, Mathew M.; Wallace, Greg; Burrage, Andrew M.; Lindsey, Scott F.; Smith, Andrew J.; Swetnam, Daniele; Manning, Brandi R.; Gray, Stacey A.; Lampert, Bernhard; Foster, Scott; Lanier, Randall; Robertson, Alice; Painter, George; Moyer, Richard W. 2011. "Efficacy of CMX001 as a Post Exposure Antiviral in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans." Viruses 3, no. 1: 47-62.